Granules India Limited — Important, 01-08-2025: General Updates

Granules India's subsidiary, Granules Life Sciences, completed its US FDA Pre-Approval Inspection at the Hyderabad facility. A single procedural 483 observation was noted, which the company will address promptly. This outcome is favorable, suggesting minor issues and clearing a key regulatory hurdle for the facility, which manufactures PFI & Finished Dosages. This operational update bodes well for product approvals and ongoing business continuity.